Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Knockdown of ST6Gal-I increases cisplatin sensitivity in cervical cancer cells

Authors: Xiaopeng Zhang, Chunchen Pan, Lei Zhou, Zhaogen Cai, Shufang Zhao, Donghong Yu

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Sialyltransferase I (ST6Gal-I) is an enzyme involved in tumor metastasis that processes sialic acid precursors into their mature form, enabling them to regulate gene expression. However, the effect of ST6Gal-I on the biological behavior of cancer cells remain unclear. This study was the first to demonstrate the influence of ST6Gal-I on cisplatin sensitivity in cervical cancer cells.

Methods

Knockdown of ST6Gal-I was performed by shRNA and HeLa cells combination with cisplatin were tested.

Results

We showed that down-regulation of ST6Gal-I promoted cell apoptosis and inhibited proliferation and invasion in cervical cancer cells. Knockdown of ST6Gal-I by RNA interference increased the sensitivity of HeLa cells to cisplatin in vitro, and reduced tumor volume and suppressed subcutaneous tumor growth in response to cisplatin treatment in a xenograft mouse model in vivo.

Conclusions

The results provide new information that ST6Gal-I plays an important role in several biological or pathological processes including drug resistance in cervical cancer and may be a potential therapeutic target to improve the response to chemotherapy in cervical cancer patients.
Appendix
Available only for authorised users
Literature
1.
Lei C, Wang Y, Huang Y, Yu H, Huang Y, Wu L, Huang L. Up-regulated miR155 reverses the epithelial-mesenchymal transition induced by EGF and increases chemo-sensitivity to cisplatin in human Caski cervical cancer cells. PLoS One. 2012;7(12):e52310.CrossRefPubMedPubMedCentral
2.
Ma D, Zhang YY, Guo YL, Li ZJ, Geng L. Profiling of microRNA-mRNA reveals roles of microRNAs in cervical cancer. Chin Med J. 2012;125(23):4270–6.PubMed
3.
Guo L, Zhu H, Lin C, Che J, Tian X, Han S, Zhao H, Zhu Y, Mao D. Associations between antioxidant vitamins and the risk of invasive cervical cancer in Chinese women: A case-control study. Sci Rep. 2015;5:13607.CrossRefPubMedPubMedCentral
4.
Shen Y, Yang L, Wang Z. Treatment of early bulky cervical cancer with neoadjuvant paclitaxel, carboplatin and cisplatin prior to laparoscopical radical hysterectomy and pelvic lymphadenectomy. Oncol Lett. 2012;3(3):641–5.PubMed
5.
Benedetti-Panici P, Greggi S, Scambia G, Amoroso M, Salerno MG, Maneschi F, Cutillo G, Paratore MP, Scorpiglione N, Mancuso S. Long-term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Eur J Cancer. 1998;34(3):341–6.CrossRefPubMed
6.
Choi CH, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS. Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2-IIB cervical carcinoma. Gynecol Oncol. 2007;104(1):64–9.CrossRefPubMed
7.
Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, Kozlowski M, Le Pechoux C, Pirker R, Pinel MI, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010;28(1):35–42.CrossRefPubMed
8.
Helbig L, Damrot J, Hulsenbeck J, Koberle B, Brozovic A, Osmak M, Fiket Z, Kaina B, Fritz G. Late activation of stress-activated protein kinases/c-Jun N-terminal kinases triggered by cisplatin-induced DNA damage in repair-defective cells. J Biol Chem. 2011;286(15):12991–3001.CrossRefPubMedPubMedCentral
9.
Li K, Chen B, Xu L, Feng J, Xia G, Cheng J, Wang J, Gao F, Wang X. Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivo. Int J Nanomedicine. 2013;8:1867–77.PubMedPubMedCentral
10.
Jiang Z, Chen BA, Xia GH, Wu Q, Zhang Y, Hong TY, Zhang W, Cheng J, Gao F, Liu LJ, et al. The reversal effect of magnetic Fe3O4 nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cells. Int J Nanomedicine. 2009;4:107–14.PubMedPubMedCentral
11.
Shen Y, Ren M, Shi Y, Zhang Y, Cai Y. Octreotide enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro. Exp Ther Med. 2011;2(6):1171–6.PubMedPubMedCentral
12.
Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4):239–52.CrossRefPubMed
13.
von Wichert G, Sheetz MP. Mechanisms of disease: the biophysical interpretation of the ECM affects physiological and pathophysiological cellular behavior. Z Gastroenterol. 2005;43(12):1329–36.CrossRef
14.
15.
Yu S, Fan J, Liu L, Zhang L, Wang S, Zhang J. Caveolin-1 up-regulates integrin alpha2,6-sialylation to promote integrin alpha5beta1-dependent hepatocarcinoma cell adhesion. FEBS Lett. 2013;587(6):782–7.CrossRefPubMed
16.
Gu J, Isaji T, Sato Y, Kariya Y, Fukuda T. Importance of N-glycosylation on alpha5beta1 integrin for its biological functions. Biol Pharm Bull. 2009;32(5):780–5.CrossRefPubMed
17.
Wang PH, Lee WL, Lee YR, Juang CM, Chen YJ, Chao HT, Tsai YC, Yuan CC. Enhanced expression of alpha 2,6-sialyltransferase ST6Gal I in cervical squamous cell carcinoma. Gynecol Oncol. 2003;89(3):395–401.CrossRefPubMed
18.
Kaneko Y, Yamamoto H, Kersey DS, Colley KJ, Leestma JE, Moskal JR. The expression of Gal beta 1,4GlcNAc alpha 2,6 sialyltransferase and alpha 2,6-linked sialoglycoconjugates in human brain tumors. Acta Neuropathol. 1996;91(3):284–92.CrossRefPubMed
19.
Dall'Olio F, Chiricolo M, D'Errico A, Gruppioni E, Altimari A, Fiorentino M, Grigioni WF. Expression of beta-galactoside alpha2,6 sialyltransferase and of alpha2,6-sialylated glycoconjugates in normal human liver, hepatocarcinoma, and cirrhosis. Glycobiology. 2004;14(1):39–49.CrossRefPubMed
20.
Lin S, Kemmner W, Grigull S, Schlag PM. Cell surface alpha 2,6 sialylation affects adhesion of breast carcinoma cells. Exp Cell Res. 2002;276(1):101–10.CrossRefPubMed
21.
22.
23.
Bian HB, Pan X, Yang JS, Wang ZX, De W. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res. 2011;30:20.CrossRefPubMedPubMedCentral
24.
Jing Z, Heng W, Xia L, Ning W, Yafei Q, Yao Z, Shulan Z. Downregulation of phosphoglycerate dehydrogenase inhibits proliferation and enhances cisplatin sensitivity in cervical adenocarcinoma cells by regulating Bcl-2 and caspase-3. Cancer Biol Ther. 2015;16(4):541–8.CrossRefPubMedPubMedCentral
25.
Yang C, Cai J, Wang Q, Tang H, Cao J, Wu L, Wang Z. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol Oncol. 2012;124(2):325–34.CrossRefPubMed
26.
27.
Zoldos V, Novokmet M, Beceheli I, Lauc G. Genomics and epigenomics of the human glycome. Glycoconj J. 2013;30(1):41–50.CrossRefPubMed
28.
Schachter H, Freeze HH. Glycosylation diseases: quo vadis? Biochim Biophys Acta. 2009;1792(9):925–30.CrossRefPubMed
29.
Stanley P, Schachter H, Taniguchi N. N-glycans. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME. Discovery and Classification of Glycan-Binding Proteins -- Essentials of Glycobiology. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2009. p. 101–14.
30.
Brockhausen I, Schachter H, Stanley P. O-GalNAc glycans. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME. Chemical and Enzymatic Synthesis of Glycans and Glycoconjugates -- Essentials of Glycobiology. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2009. p. 115–28.
31.
Miyagi T, Takahashi K, Hata K, Shiozaki K, Yamaguchi K. Sialidase significance for cancer progression. Glycoconj J. 2012;29(8-9):567–77.CrossRefPubMed
32.
Dall'Olio F, Malagolini N, Trinchera M, Chiricolo M. Mechanisms of cancer-associated glycosylation changes. Front Biosci (Landmark Ed). 2012;17:670–99.CrossRef
33.
34.
Adamczyk B, Tharmalingam T, Rudd PM. Glycans as cancer biomarkers. Biochim Biophys Acta. 2012;1820(9):1347–53.CrossRefPubMed
35.
36.
Yamaguchi K, Shiozaki K, Moriya S, Koseki K, Wada T, Tateno H, Sato I, Asano M, Iwakura Y, Miyagi T. Reduced susceptibility to colitis-associated colon carcinogenesis in mice lacking plasma membrane-associated sialidase. PLoS One. 2012;7(7):e41132.CrossRefPubMedPubMedCentral
37.
Varki NM, Varki A. Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab Invest. 2007;87(9):851–7.CrossRefPubMed
38.
39.
40.
Audry M, Jeanneau C, Imberty A, Harduin-Lepers A, Delannoy P, Breton C. Current trends in the structure-activity relationships of sialyltransferases. Glycobiology. 2011;21(6):716–26.CrossRefPubMed
41.
42.
Tsuji S. Molecular cloning and functional analysis of sialyltransferases. J Biochem. 1996;120(1):1–13.CrossRefPubMed
43.
Harduin-Lepers A, Recchi MA, Delannoy P. 1994, the year of sialyltransferases. Glycobiology. 1995;5(8):741–58.CrossRefPubMed
44.
Datta AK. Comparative sequence analysis in the sialyltransferase protein family: analysis of motifs. Curr Drug Targets. 2009;10(6):483–98.CrossRefPubMed
45.
Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S, Delannoy P. The human sialyltransferase family. Biochimie. 2001;83(8):727–37.CrossRefPubMed
46.
Costa-Nogueira C, Villar-Portela S, Cuevas E, Gil-Martin E, Fernandez-Briera A. Synthesis and expression of CDw75 antigen in human colorectal cancer. BMC Cancer. 2009;9:431.CrossRefPubMedPubMedCentral
47.
Lise M, Belluco C, Perera SP, Patel R, Thomas P, Ganguly A. Clinical correlations of alpha2,6-sialyltransferase expression in colorectal cancer patients. Hybridoma. 2000;19(4):281–6.CrossRefPubMed
48.
Phillips DC, Xiao Y, Lam LT, Litvinovich E, Roberts-Rapp L, Souers AJ, Leverson JD. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J. 2015;5:e368.CrossRefPubMedPubMedCentral
49.
Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47–59.CrossRefPubMed
Metadata
Title
Knockdown of ST6Gal-I increases cisplatin sensitivity in cervical cancer cells
Authors
Xiaopeng Zhang
Chunchen Pan
Lei Zhou
Zhaogen Cai
Shufang Zhao
Donghong Yu
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2981-y

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

Systematic review: brain metastases from colorectal cancer—Incidence and patient characteristics

Research article

Mesenchymal stem cells enhance the metastasis of 3D-cultured hepatocellular carcinoma cells

Case report

Complete response of extramedullary relapse in breast of acute T lymphoblastic leukemia after bone marrow transplantation to chemoradiotherapy: a case report and literature review

Research article

A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study

Research article

Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns

Research article

Characterization of various cell lines from different ampullary cancer subtypes and cancer associated fibroblast-mediated responses
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits